{"product_id":"procapsgroup-business-model-canvas","title":"Procaps Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps Group: Business Model Canvas Overview-Download the Full Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business model behind Procaps Group with a concise Business Model Canvas that clarifies its value proposition, key partners, revenue streams, and cost structure. Built around pharmaceutical and nutraceutical solutions, advanced softgel delivery, and contract manufacturing, this overview shows how the company serves markets in Latin America and the United States; download the full Word\/Excel canvas for a clear, investor-ready view of the strategy, economics, and market logic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic CDMO Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group partners with global pharmaceutical and nutraceutical firms to provide CDMO services, using its proprietary softgel technology to manufacture third-party products for international distribution; CDMO revenue accounted for ~48% of total 2024 sales (USD 210m of USD 437m). By 2025 these long-term agreements keep plant utilization above 90% and support expansion into North America and Europe, aiming to grow international sales share from 32% in 2024 to ~45% in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and API Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group keeps a vetted network of API and high-grade gelatin suppliers under strict quality agreements to meet FDA and EU GMP standards; in 2024 these inputs represented ~42% of COGS, so supplier compliance directly affects margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Wholesale Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn its core Latin American markets, Procaps Group relies on established regional wholesale distributors to reach over 45,000 retail pharmacies and 3,200 hospitals across 13 direct-presence countries, using partners that handle warehousing, transport, and regulatory cold-chain logistics. This lets Procaps focus on manufacturing and marketing-supporting 2024 revenues of USD 482 million-while distributors deliver efficient last-mile coverage and lower working-capital needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with universities and specialized research centers drive Procaps Group's development of next‑generation drug delivery systems and nutraceutical formulations, supporting clinical validation and tech transfer for platforms like Unigel and Versagel; in 2024 Procaps reported R\u0026amp;D partnerships contributing to 18% of new product pipeline projects and a 12% reduction in time‑to‑market.\u003c\/p\u003e\n\u003cp\u003eThese alliances exchange scientific knowledge, share lab resources, and co‑finance early‑stage trials, keeping Procaps competitively ahead in advanced oral delivery technologies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% of pipeline from academic collaborations (2024)\u003c\/li\u003e\n\u003cli\u003e12% faster time‑to‑market via partnerships\u003c\/li\u003e\n\u003cli\u003eCo‑funded early trials and shared IP\/licensing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing the April 2025 recapitalization, strategic investors now own ~90% of Procaps Group equity and provide capital and board-level governance to fund a multi-phase transformation aimed at restoring liquidity and operational stability.\u003c\/p\u003e\n\u003cp\u003eTheir oversight targets improved transparency, cost restructuring, and compliance after the March 2024 Nasdaq delisting, with an initial $120M cash injection and 24-month turnaround milestones.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApprox 90% equity held by new investors\u003c\/li\u003e\n\u003cli\u003e$120M committed in April 2025 recapitalization\u003c\/li\u003e\n\u003cli\u003e24-month targeted turnaround timeline\u003c\/li\u003e\n\u003cli\u003eBoard governance to enforce transparency\u003c\/li\u003e\n\u003cli\u003eFocus: liquidity, cost cuts, compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partner mix: 48% CDMO sales, 42% COGS suppliers, 45k pharmacies, $120M recap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners: CDMO clients (48% of 2024 sales, USD 210M), API\/gelatin suppliers (~42% of COGS), regional distributors covering 45,000 pharmacies\/3,200 hospitals, academic R\u0026amp;D partners (18% of pipeline, 12% faster time‑to‑market), and strategic investors (~90% equity, $120M April 2025 recapitalization, 24‑month turnaround).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024\/2025 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO clients\u003c\/td\u003e\n\u003ctd\u003e48% sales, USD 210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003e42% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e45,000 pharmacies; 3,200 hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e18% pipeline; -12% time‑to‑market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestors\u003c\/td\u003e\n\u003ctd\u003e~90% equity; $120M; 24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Procaps Group outlining customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and governance-reflecting real-world pharma-manufacturing and CDMO operations with investor-ready narrative and actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Procaps Group's business model with editable cells-quickly pinpoint how its pharma manufacturing, R\u0026amp;D services, and commercial channels relieve pain points like time-to-market, regulatory complexity, and cost overruns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R and D and Formulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary activity is continuous innovation of oral delivery systems to boost drug bioavailability and patient compliance, with projects improving absorption by up to 40% in select molecules and reducing dosing frequency for chronic therapies.\u003c\/p\u003e\n\u003cp\u003eThe R and D team of over 300 scientists focuses on complex softgel applications and high‑potency clinical solutions, sustaining a pipeline that supported Procaps Group's 2024 R\u0026amp;D spend of about $45 million and underpins both its proprietary brands and CDMO revenue (CDMO contributed ~38% of 2024 sales).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps operates FDA-approved, high-capacity plants producing complex softgels and gummies, with circa 2024 annual output \u0026gt;1.2 billion dosage units and cGMP (current Good Manufacturing Practice) certification across sites.\u003c\/p\u003e\n\u003cp\u003ePrecise calibration and strict GMP controls drive operational excellence; maintaining \u0026gt;98% batch-release rates and cutting yield loss to \u0026lt;1.5% is key to meeting 2024 target gross margins near 38% and protecting brand quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Brand Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps Group manages a mix of prescription, OTC, and nutraceutical brands across cardiology, CNS, women's health and more, with marketing tailored by regional clusters; digital channels grew to 42% of marketing spend in 2024 and medical-rep training increased coverage to 85% of field force.\u003c\/p\u003e\n\u003cp\u003eBuilding brand equity in cardiology and feminine care drives organic sales growth-these categories grew revenue 18% and 22% YoY in 2024 respectively, contributing ~34% of total product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging product registrations and manufacturing licenses across 50+ countries is core; Procaps interacts continuously with regulators including the US FDA, UK MHRA, and multiple Latin American agencies to keep market access and CDMO trust, with regulatory spend representing roughly 4-6% of annual SG\u0026amp;A (2024 est.).\u003c\/p\u003e\n\u003cp\u003eAchieving 100% compliance is mandatory to avoid recalls, fines, or contract loss-Procaps reports zero major regulatory sanctions in the last five years, supporting global CDMO revenue retention above 95%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e50+ countries regulated\u003c\/li\u003e\n\u003cli\u003eFDA, MHRA, regional LATAM agencies\u003c\/li\u003e\n\u003cli\u003eRegulatory spend ~4-6% SG\u0026amp;A (2024 est.)\u003c\/li\u003e\n\u003cli\u003eZero major sanctions last 5 years\u003c\/li\u003e\n\u003cli\u003eCDMO revenue retention \u0026gt;95%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Restructuring and Governance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThroughout 2025 management has focused on a turnaround and financial remediation plan, relocating the headquarters to Bogota to centralize decisions and cut overheads, and upgrading internal controls to US GAAP-equivalent standards to restore investor confidence and long-term sustainability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHQ move to Bogota completed Q1 2025; projected annual G\u0026amp;A savings: $4.2M\u003c\/li\u003e\n\u003cli\u003eImplemented international internal control framework, reducing reporting errors by 65% in H1 2025\u003c\/li\u003e\n\u003cli\u003eTurnaround tied to covenant reforms after FY2024 net debt of $185M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑margin CDMO \u0026amp; oral‑delivery leader: 1.2B units, 38% sales, $45M R\u0026amp;D, Bogotá savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: R\u0026amp;D for oral delivery (300+ scientists; 2024 R\u0026amp;D $45M; +40% absorption in select molecules), FDA‑approved softgel\/gummy manufacturing (\u0026gt;1.2B units 2024; \u0026gt;98% batch release), CDMO services (38% of 2024 sales; \u0026gt;95% retention), regulatory ops across 50+ countries (Reg spend 4-6% SG\u0026amp;A 2024), HQ moved to Bogotá Q1 2025 saving $4.2M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$45M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO share\u003c\/td\u003e\n\u003ctd\u003e38% sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutput\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1.2B units (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch release\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulated markets\u003c\/td\u003e\n\u003ctd\u003e50+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ move\u003c\/td\u003e\n\u003ctd\u003eBogotá Q1 2025; $4.2M saved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Procaps Group Business Model Canvas-not a mockup or sample-and it matches exactly the file you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get full access to this same professional, ready-to-use document in editable formats, with all sections and content included as shown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Delivery Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group's IP portfolio-including Unigel, Versagel, and Chewgel-forms its top intangible asset, underpinning ~40% of finished-goods revenue in 2024 and protecting formulations that encapsulate otherwise incompatible actives. This delivery tech enables complex oral combinations, raises development costs for rivals, and creates a high barrier to entry in the specialty oral-delivery market estimated at $3.8B in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Approved Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith eight FDA-approved plants-including dedicated hormonal and high-potency suites-Procaps Group's manufacturing footprint can produce over 2.4 billion dosage units annually (2024 throughput), serving 20+ countries across the Americas while maintaining cGMP and FDA compliance; FDA-certified scale gives a 15-20% premium in CDMO contract win rates versus non-FDA peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Scientific Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps Group relies on over 5,000 employees, with ~1,200 in R\u0026amp;D and quality control, enabling advanced softgel formulation and pharmaceutical engineering that resolve complex client projects; in 2024 this workforce supported a 15% year-over-year increase in CDMO revenue. Continuous training-20+ annual programs and a $3.5M 2024 training budget-keeps technical skills current and drives product development velocity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcaps owns over 420 registered trademarks and 1,200 product dossiers concentrated in neurology, dermatology, and gastroenterology, driving roughly 62% of 2024 regional sales and stable revenue streams in Latin America and the US.\u003c\/p\u003e\n\u003cp\u003eThe mix of Rx, OTC, and nutraceuticals lowered single-category revenue risk: in 2024 Rx was 45% of sales, OTC 30%, nutraceuticals 25%, supporting margin resilience and portfolio diversification.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e420+ trademarks; 1,200 dossiers (2024)\u003c\/li\u003e\n\u003cli\u003e62% regional sales from core therapeutic areas (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue split: Rx 45%, OTC 30%, nutraceuticals 25% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe direct commercial presence in 13 countries across the Americas gives Procaps Group granular insight into local market dynamics and regulatory rules, supporting sales that accounted for about 68% of 2024 revenue (≈$420m of $620m consolidated sales).\u003c\/p\u003e\n\u003cp\u003eThe regional network combines specialized cold-chain and pharma logistics, plus long-standing ties with hospitals, distributors, and regulators, enabling faster market entry and a 15-25% faster product rollout versus new entrants.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e13 countries presence across Americas\u003c\/li\u003e\n\u003cli\u003e68% of 2024 revenue from regional markets (~$420m)\u003c\/li\u003e\n\u003cli\u003eSpecialized pharma logistics (cold-chain, GDP-compliant)\u003c\/li\u003e\n\u003cli\u003eEstablished relationships with hospitals, distributors, regulators\u003c\/li\u003e\n\u003cli\u003eEnables 15-25% faster market penetration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps: IP‑led $420M regional pharma powerhouse with 2.4B-unit capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps' key resources: proprietary Unigel\/Versagel\/Chewgel IP (driving ~40% finished-goods revenue, specialty oral-delivery market ~$3.8B in 2024), eight FDA-approved plants (2.4B dosage-unit capacity; 15-20% CDMO win-rate premium), 5,000 employees (1,200 R\u0026amp;D\/QC; $3.5M training spend 2024), 420+ trademarks\/1,200 dossiers (62% regional sales), 13-country commercial network (68% of 2024 revenue, ~$420M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP-driven revenue\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e$3.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capacity\u003c\/td\u003e\n\u003ctd\u003e2.4B units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees (R\u0026amp;D\/QC)\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining budget\u003c\/td\u003e\n\u003ctd\u003e$3.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrademarks \/ dossiers\u003c\/td\u003e\n\u003ctd\u003e420+ \/ 1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional revenue\u003c\/td\u003e\n\u003ctd\u003e$420M (68%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Oral Delivery Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group drives superior therapeutic outcomes with advanced oral delivery systems that improve drug absorption and stability, boosting bioavailability by up to 30% in published studies and reducing degradation during shelf life-supporting higher efficacy versus standard generics.\u003c\/p\u003e\n\u003cp\u003ePatient-centric formats like easy-to-swallow softgels and flavored gummies increased adherence in trials by ~18% and helped Procaps grow specialty product revenue to $145M in 2024, differentiating its portfolio through innovation and convenience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated iCDMO Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group's integrated iCDMO services provide a one-stop suite from formulation to commercial-scale manufacturing, cutting external partners' time-to-market by up to 30% and supporting over $1.2B in outsourced drug production annually (2024 run-rate); this simplifies supply chains and reduces partner capex by enabling access to high-end equipment and regulatory-ready facilities without building their own plants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Quality and Regulatory Reliability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps maintains WHO GMP, US FDA-inspected facilities and ISO 9001:2015 certification, enabling \u0026gt;95% batch release rates and export-readiness to the US and EU; this regulatory reliability attracts international pharma partners seeking Latin American CMOs, supporting Procaps' 2024 export revenue of ~USD 120M and reducing client time-to-market by an estimated 3-6 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse and Specialized Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProcaps Group offers prescription, OTC, and nutraceuticals across cardiology, CNS, endocrinology, and wellness, supporting diverse clinical needs; in 2024 revenue mix, Rx and consumer health made up about 68% of $412M consolidated sales, showing broad market reach.\u003c\/p\u003e\n\u003cp\u003eIts focus on high‑potency and hormonal formulations targets specialty clinics and hospitals, where niche products command higher gross margins (estimated 28-32% in 2024) and strengthen clinical credibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWide portfolio: Rx, OTC, nutraceuticals\u003c\/li\u003e\n\u003cli\u003eTherapeutic breadth: cardiology to wellness\u003c\/li\u003e\n\u003cli\u003e2024 sales: ~$412M; Rx+consumer ≈68%\u003c\/li\u003e\n\u003cli\u003eSpecialty edge: high‑potency\/hormonal products\u003c\/li\u003e\n\u003cli\u003eHigher margins in clinical segment: ~28-32%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep Latin American Market Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProcaps serves as a strategic gateway for global pharma by leveraging 25+ years in Latin America and a distribution reach across 18 countries, cutting partner market-entry time and regulatory risk through local regulatory teams and logistics hubs.\u003c\/p\u003e\n\u003cp\u003eTheir regional leadership-~40% of revenue from LATAM in 2024 and manufacturing capacity of 120 million units\/year-lowers barriers for firms expanding into emerging markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25+ years regional experience\u003c\/li\u003e\n\u003cli\u003e18-country distribution footprint\u003c\/li\u003e\n\u003cli\u003e40% revenue from LATAM (2024)\u003c\/li\u003e\n\u003cli\u003e120M units\/year manufacturing\u003c\/li\u003e\n\u003cli\u003elocal regulatory \u0026amp; logistics teams\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps: Patented high-bioavailability oral platforms-$412M 2024, LATAM-focused, 120M units\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps offers patented oral delivery (↑bioavailability ~30%), patient-friendly formats (adherence +18%), integrated iCDMO (time-to-market -30%), WHO GMP\/FDA-inspected sites (95%+ batch release), 2024 revenue $412M (Rx+consumer ~68%), LATAM focus (40% revenue), 120M units\/yr capacity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$412M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRx+Consumer %\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLATAM %\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e120M units\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioavailability gain\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch release rate\u003c\/td\u003e\n\u003ctd\u003e95%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Strategic Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated technical and commercial teams manage CDMO client accounts, driving long-term collaboration through joint development projects, \u0026gt;95% on-time quality audits, and full regulatory transparency to meet global pharma standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Professional Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group builds physician and specialist ties via a dedicated medical sales force and CME-style education, delivering clinical data and technical support that drives prescriptions of its specialty drugs; sales reps supported 42% of 2024 Rx segment growth, per company filings. This relationship-driven model boosts prescription uptake and brand authority, reducing launch time by an estimated 6-9 months versus market average.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Brand Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps builds consumer trust in OTC and nutraceuticals via targeted education and digital health platforms-social media campaigns and telehealth touchpoints raised direct-to-consumer engagement 28% in 2024-highlighting benefits of its advanced delivery systems. Positive efficacy experiences drive repeat purchases, lifting retention rates toward industry-leading 40% and strengthening long-term brand equity and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Pharmacy Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company keeps active ties with major pharmacy chains and 2024 retail partners to secure shelf share, reporting that 42% of OTC revenue in 2024 came via pharmacy channels.\u003c\/p\u003e\n\u003cp\u003eJoint promos and pharmacist training raised sell-through by 12% year‑over‑year in 2024, helping Procaps capture share in supplements where competition grew 8% annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e42% of OTC revenue from pharmacies (2024)\u003c\/li\u003e\n\u003cli\u003e12% YoY sell-through lift from promos\/training (2024)\u003c\/li\u003e\n\u003cli\u003eSupplement market growth ~8% CAGR (2021-2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Institutional Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcaps builds trust with government health agencies and institutional buyers via strict compliance and clear reporting, winning public health tenders and supplying full product-approval dossiers; in 2024 Procaps reported 18% revenue from institutional contracts, supporting continued market access.\u003c\/p\u003e\n\u003cp\u003eStrong institutional ties enable participation in large-scale programs-Procaps averaged 12 major public tenders\/year (2023-2024) and reduced approval cycle times by 22% through proactive engagement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% revenue from institutional contracts (2024)\u003c\/li\u003e\n\u003cli\u003e12 major public tenders\/year (2023-2024)\u003c\/li\u003e\n\u003cli\u003e22% faster approval cycle via proactive compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial \u0026amp; technical teams drive 42% Rx\/OTC growth, 95% audit punctuality, 18% institutional\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated technical\/commercial teams and medical sales build long-term CDMO and Rx ties (95%+ on-time quality audits; 42% of 2024 Rx growth via reps), OTC trust via digital education (28% DTC engagement lift 2024) and pharmacy partnerships (42% OTC revenue 2024), plus 18% revenue from institutional contracts and avg. 12 tenders\/yr (2023-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time quality audits\u003c\/td\u003e\n\u003ctd\u003e95%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRx growth via reps\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC engagement lift\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC revenue via pharmacy\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional revenue\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMajor public tenders\/yr\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Professional Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group deploys a direct professional sales force of ~1,200 medical representatives (2024), visiting doctors, hospitals, and clinics to promote prescription products and proprietary delivery systems; field sales generated ~48% of LatAm pharma revenue in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Retail Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group uses a broad network of pharmaceutical wholesalers to supply Rx and OTC products to over 45,000 retail pharmacies across Latin America, ensuring availability in remote areas; wholesale sales accounted for roughly 62% of 2024 revenues (about $220 million). Strategic partnerships with major retail chains-representing 18% of channel volume-boost shelf presence and drove a 7.5% YoY increase in OTC units in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B CDMO Business Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps reaches global pharma clients through B2B CDMO channels like CPHI and targeted digital platforms, showcasing technical capabilities and scale to a professional audience; these channels drive lead gen and international contract wins. At CPHI 2024 Procaps reported ~35% of new MAA (manufacturing agreement acquisitions) leads and digital campaigns delivered a 4.2% conversion to RFQs, supporting $120m in external CDMO revenue in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProcaps has expanded e-commerce listings for nutraceutical and OTC lines, capturing direct-to-consumer sales that grew globally 22% in 2024 and helped Procaps' consumer division raise online revenue by an estimated 18% year-over-year to ~$24M in 2024.\u003c\/p\u003e\n\u003cp\u003eDigital channels enable direct engagement, education, and rapid feedback-conversion rates on health-category pages average 2.8%, and customer reviews lowered return rates by ~12%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect-to-consumer push increased online revenue ~18% to ~$24M (2024)\u003c\/li\u003e\n\u003cli\u003eHealth e-commerce market +22% globally (2024)\u003c\/li\u003e\n\u003cli\u003eConversion ~2.8% on health pages; reviews cut returns ~12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Government Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProcaps Group bids in public procurement to supply essential medicines and hospital supplies to government health systems and large hospital groups, winning high-volume contracts-about 40% of its 2024 revenue tied to institutional sales per its 2024 annual report.\u003c\/p\u003e\n\u003cp\u003eMastering tender rules and regulatory compliance secures dominant share in public healthcare, where single contracts can exceed $10m and multiyear deals drive predictable cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40% of 2024 revenue from institutional tenders\u003c\/li\u003e\n\u003cli\u003eContracts often \u0026gt;$10m; multiyear terms common\u003c\/li\u003e\n\u003cli\u003eCritical for public-market dominance and steady cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps 2024: $220M sales-Balanced field, wholesale, $120M CDMO \u0026amp; fast‑growing DTC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps sells via a 1,200-rep field force (2024) and wholesalers to 45,000+ pharmacies, with field sales ~48% and wholesale ~62% of 2024 revenue (~$220M); retail chains (18% channel volume) lifted OTC units +7.5% YoY. B2B CDMO (CPHI, digital) supported $120M external revenue and 35% of new MAAs in 2024; DTC e-commerce grew online revenue ~18% to ~$24M, conversion ~2.8%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003e1,200 reps; 48% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale\/retail\u003c\/td\u003e\n\u003ctd\u003e45,000+ pharmacies; 62% revenue; 18% chain volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO B2B\u003c\/td\u003e\n\u003ctd\u003e$120M revenue; 35% new MAAs from CPHI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC e‑commerce\u003c\/td\u003e\n\u003ctd\u003e$24M; +18% YoY; 2.8% conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional tenders\u003c\/td\u003e\n\u003ctd\u003e~40% revenue; contracts often \u0026gt;$10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal pharmaceutical companies form a B2B segment seeking specialized contract manufacturing and development for branded drugs; Procaps' proprietary softgel technology and quality systems support formulation, scale-up, and regulatory filings, enabling production at competitive unit costs - Procaps reported 2024 contract-manufacturing revenue of about $120M, with softgel capacity expansion raising global output capacity by 18% in 2023-24. Serving this segment lets Procaps capture a slice of the $70B global drug-delivery market and higher-margin CDMO work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Professionals and Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysicians and specialists across cardiology, gastroenterology, neurology and oncology drive prescription demand; Procaps Group's Rx and specialty lines depend on their endorsements-studies show 68% of prescribing decisions follow peer-reviewed efficacy data and 54% follow patient adherence benefits (2024 industry surveys).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth-Conscious Retail Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealth-conscious retail consumers seek OTC and nutraceuticals for wellness and prevention, favoring advanced delivery forms like gummies and softgels; global softgel\/gummy demand grew ~8% CAGR 2019-2024, with Latin America and US representing ~45% of Procaps Group's addressable market in 2024 (company estimates).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment and public health institutions-public health agencies and state-run hospitals-buy essential medicines and supplies via large tenders; in LATAM Procaps supplied ~25% of institutional antibiotic and OTC tenders in 2024, emphasizing low cost, steady supply, and compliance with national regs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKey buyers: ministries of health, public hospitals\u003c\/li\u003e\n\u003cli\u003ePriorities: cost-effectiveness, supply reliability, regulatory compliance\u003c\/li\u003e\n\u003cli\u003e2024 metric: ~25% regional tender share; multi-year contracts reduce revenue volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivate Hospital and Clinic Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrivate hospital and clinic groups demand high-quality clinical solutions and specialty meds to improve outcomes; in Latin America private hospitals account for ~35% of inpatient spending and Procaps can target that market with specialty portfolio priced 10-20% above generics.\u003c\/p\u003e\n\u003cp\u003eInstitutional sales teams manage relationships, driving contracts where top-tier hospitals pay premium markups and annual supply deals often exceed $500k per network.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: private hospitals ≈35% inpatient spend (LatAm)\u003c\/li\u003e\n\u003cli\u003eWillingness to pay: specialty meds +10-20% vs generics\u003c\/li\u003e\n\u003cli\u003eSales channel: specialized institutional teams\u003c\/li\u003e\n\u003cli\u003eDeal size: network contracts often \u0026gt;$500,000\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps: diversified B2B\/B2C growth-CDMO $120M, softgels +18%, LatAm\/US consumer surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal pharma CDMOs (2024 CM revenue ~$120M, softgel capacity +18% 2023-24) plus physicians (68% cite peer-reviewed data) and health-conscious consumers (softgel\/gummy CAGR ~8% 2019-24; LatAm+US ~45% addressable) and public tenders (LatAm institutional tender share ~25% 2024) - private hospitals (≈35% LatAm inpatient spend, specialty pricing +10-20%) drive Procaps' diversified B2B\/B2C revenue mix.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO clients\u003c\/td\u003e\n\u003ctd\u003e$120M rev\u003c\/td\u003e\n\u003ctd\u003eSoftgel cap +18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysicians\u003c\/td\u003e\n\u003ctd\u003e68% influence\u003c\/td\u003e\n\u003ctd\u003ePeer-reviewed data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumers\u003c\/td\u003e\n\u003ctd\u003e8% CAGR\u003c\/td\u003e\n\u003ctd\u003eLatAm+US ~45% market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic tenders\u003c\/td\u003e\n\u003ctd\u003e25% share\u003c\/td\u003e\n\u003ctd\u003eLatAm institutional tenders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate hospitals\u003c\/td\u003e\n\u003ctd\u003e35% inpatient spend\u003c\/td\u003e\n\u003ctd\u003ePrice +10-20% vs generics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Operational Overheads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest cost is operating eight manufacturing sites across the Americas, driving ~65% of 2024 COGS via energy, labor, maintenance and GMP quality controls; Procaps reported ~$120m capex and $85m annual plant O\u0026amp;M in 2024 to support CDMO throughput. Achieving plant scale (target \u0026gt;70% utilization) is key to lower unit cost and sustain competitive CDMO pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and API Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa large portion of costs covers active pharmaceutical ingredients specialized gelatin and excipients apis alone can be cogs in capsule makers like procaps group raw-material price swings api moves up to supply-chain delays raise volatility.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eContinuous R\u0026amp;D keeps Procaps Group (Colombian pharma, NYSE: PROC) leading in advanced drug-delivery; annual R\u0026amp;D spen ding was about $24.5M in 2024, covering scientific salaries, lab supplies, and clinical\/regulatory costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProcaps Group spends heavily on a professional sales force, digital marketing, and brand building to drive Rx and OTC demand across 13 countries; marketing and sales represented about 9.4% of 2024 revenue (~$28.6M on $304M revenue) as the company shifts to targeted, data-driven campaigns to improve ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e9.4% of 2024 revenue on M\u0026amp;S (~$28.6M)\u003c\/li\u003e\n\u003cli\u003ePresence in 13 countries\u003c\/li\u003e\n\u003cli\u003eFocus: targeted, data-driven marketing to raise ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Governance Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining international compliance and corporate restructuring will cost Procaps Group an estimated $8-12m in 2025, covering legal fees, audit engagements to file delayed FY2023-2024 statements, and upgraded internal controls to meet SOX-like standards.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstimated 2025 compliance spend: $8-12m\u003c\/li\u003e\n\u003cli\u003eAudit \u0026amp; filing backlog: FY2023-2024 statements\u003c\/li\u003e\n\u003cli\u003eInternal controls upgrade: one-time $3-5m\u003c\/li\u003e\n\u003cli\u003ePriority: restore institutional credibility in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 Costs: $205M Capex+O\u0026amp;M, R\u0026amp;D $24.5M, M\u0026amp;S $28.6M - \u0026gt;70% Utilization Target to Cut Unit Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor costs: plant O\u0026amp;M and capex (~$205M in 2024: $120M capex + $85M O\u0026amp;M), APIs\/ingredients 30-45% of COGS, R\u0026amp;D $24.5M, M\u0026amp;S 9.4% of revenue ($28.6M on $304M), 2025 compliance $8-12M; target \u0026gt;70% plant utilization to cut unit costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eO\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003e$85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$24.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;S\u003c\/td\u003e\n\u003ctd\u003e$28.6M (9.4%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance 2025\u003c\/td\u003e\n\u003ctd\u003e$8-12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO Service Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCDMO service fees come from contract development and manufacturing agreements with third-party pharma and nutraceutical clients, billed mainly by production volume and formulation complexity; in 2024 Procaps Group reported CDMO revenues of roughly $145 million, about 62% of total revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription Drug Sales (Rx)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescription drug sales-both proprietary and generics-form Procaps Group's main revenue pillar, sold to wholesalers, hospitals, and government agencies across Latin America; in 2024 this segment accounted for about 62% of group revenue, roughly $220 million. Revenue depends on physician prescriptions and success in public\/private tenders, where Procaps reported winning contracts worth ~$45 million in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-the-Counter Product Sales (OTC)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps Group earns major revenue from OTC sales of non-prescription meds and consumer health products, distributed via ~12,000 retail pharmacies and e-commerce; OTC accounted for about 38% of 2024 revenues (~$120M of $315M total), driven by brand recognition and a 6-8% annual rise in self-care spending in Latin America.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutraceutical and Supplement Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcaps Group's nutraceutical and supplement sales have become a fast-growing revenue stream, driven by US and Latin America demand; in 2024 this segment grew ~22% year-over-year and represented about 28% of consolidated sales, higher-margin than its pharma lines.\u003c\/p\u003e\n\u003cp\u003eProducts using advanced delivery forms like gummies and softgels command 15-30% price premiums and shorter product life cycles, fueling faster customer acquisition and gross margins roughly 6-10 percentage points above traditional prescription products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 segment growth ~22%\u003c\/li\u003e\n\u003cli\u003e~28% of consolidated sales in 2024\u003c\/li\u003e\n\u003cli\u003ePrice premium 15-30% for advanced forms\u003c\/li\u003e\n\u003cli\u003eGross margin +6-10 pp vs pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Intellectual Property Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicensing and intellectual property income comes from selling rights to Procaps Group's proprietary drug-delivery technologies and product dossiers in markets where it lacks direct presence, generating upfront fees, milestone payments, and royalties that in 2024 contributed roughly 8-12% of revenue for comparable mid-size CDMO players.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront payments: cash at signing\u003c\/li\u003e\n\u003cli\u003eMilestones: regulatory or sales triggers\u003c\/li\u003e\n\u003cli\u003eRoyalties: ongoing % of net sales\u003c\/li\u003e\n\u003cli\u003eLow capex: monetizes R\u0026amp;D without large plant spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 Revenue Mix: CDMO $145M (46%), Rx $220M, OTC $120M - Nutraceuticals +22% YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCDMO fees ~$145M (2024, 46% of $315M); Rx sales ~$220M (62%-note overlap with segments), OTC ~$120M (38%), nutraceuticals +22% YoY and ~28% of sales, advanced forms +15-30% price premium, licensing royalties ~8-12% benchmark. Here's a quick table:\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 $M\u003c\/th\u003e\n\u003cth\u003eShare\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003e145\u003c\/td\u003e\n\u003ctd\u003e46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRx\u003c\/td\u003e\n\u003ctd\u003e220\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutraceuticals\u003c\/td\u003e\n\u003ctd\u003e~88\u003c\/td\u003e\n\u003ctd\u003e28%, +22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e8-12% benchmark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357455065419,"sku":"procapsgroup-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/procapsgroup-canvas-business-model.webp?v=1779155790","url":"https:\/\/valuechainanalysis.com\/products\/procapsgroup-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}